Search

CN-122010871-A - Compounds for inhibiting PTPN proteins and uses thereof

CN122010871ACN 122010871 ACN122010871 ACN 122010871ACN-122010871-A

Abstract

The application discloses a compound which is a compound shown in a formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The compound of the application can effectively inhibit PTPN protein activity and can effectively prevent and treat PTPN protein related diseases.

Inventors

  • XIE RUI
  • LIU YAN
  • YANG YONG
  • ZHUANG HONG
  • HUANG HUIYA
  • XU ZENGJUN

Assignees

  • 艾斯拓康生物医药(天津)有限公司

Dates

Publication Date
20260512
Application Date
20250409
Priority Date
20241030

Claims (18)

  1. 1. A compound which is a compound of formula (I), or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof: Wherein each R 1 、R 2 、R 3 is independently selected from H, -OH, halogen, -C 1～6 alkyl, -C 1～6 haloalkyl, or-C 1～6 hydroxyalkyl; A is selected from the group consisting of-C 1～6 alkylene, * Is connected with B; ring a' is selected from 7-10 membered heterocycloalkylene optionally substituted with one or more R a ; Ring A' is selected from 5-6 membered cycloalkylene optionally substituted with one or more R a , 5-6 membered heterocycloalkylene optionally substituted with one or more R a ; Ring A' "is selected from 5-10 membered cycloalkylene optionally substituted with one or more R a , 5-10 membered heterocycloalkylene optionally substituted with one or more R a ; Ring L is selected from 4-10 membered heterocycloalkylene optionally substituted with one or more R a ; r 4 is selected from the group consisting of a null, or-C 1～6 alkylene; r 5 is selected from H, or-C 1～6 alkyl; R 6 is selected from the group consisting of null, -C (O) -C 1～6 alkylene, -S (O) 2 -、-S(O) 2 -C 1～6 alkylene, or-C 1～6 alkylene; R 7 is selected from-C 1～10 alkyl; B is selected from the group consisting of empty, -C 1～10 alkyl optionally substituted with one or more halo, -C 2～10 alkenyl optionally substituted with one or more R b , -C 2～10 alkynyl optionally substituted with one or more R b , -3-4 membered monocycloalkyl optionally substituted with one or more R b , -5-10 membered monocycloalkyl optionally substituted with one or more R b , -3-10 membered heteromonocycloalkyl optionally substituted with one or more R b , -6-20 membered bicyclic optionally substituted with one or more R b , -6-20 membered heterobicyclic optionally substituted with one or more R b , -5-12 membered spirocyclic optionally substituted with one or more R b , -5-12 membered heterospirocyclic optionally substituted with one or more R3496, -5-12 membered bridged ring optionally substituted with one or more R b , -5-12 membered heterobridged ring optionally substituted with one or more R b , -5-12 membered heterobridged ring optionally substituted with one or more R b -12 membered and optionally substituted with one or more R b ; B is empty and A is selected from Each R a is independently selected from-OH, halogen, oxo (=o), -C 1～6 alkyl, -C 1～6 haloalkyl, -C 1～6 alkoxy; Each R b is independently selected from the group consisting of-OH, -C 0～6 alkylene-CN, halogen, oxo (= O), -S (O) 2 -C 1～6 alkyl, -C 1～6 alkyl, -C 1～6 haloalkyl, -C 1～6 hydroxyalkyl, -C 0～6 alkylene-C 1～6 alkoxy, -C 2～10 alkenyl, -C 2～10 alkynyl, -C (O) -C 1～6 alkyl, -C (O) -C 1～6 alkoxy, -C 0～6 alkylene- (3-10) cycloalkyl, -C 0～6 alkyleneoxy- (3-10) cycloalkyl, -C 0～6 alkylene- (3-10) heterocycloalkyl, -C 0～6 alkylene- (6-10) aryl, -C 0～6 alkylene- (5-10) membered heteroaryl, -S (O) 2 - (6-10) membered aryl, -S (O) 2 - (5-10) membered heteroaryl.
  2. 2. The compound of claim 1, wherein the compound satisfies the following condition: 1) When B is selected from 3-4 membered monocycloalkyl optionally substituted with one or more R b , or 3-10 membered heteromonocycloalkyl optionally substituted with one or more R b , A is selected from R 4 and R 6 are null; 3) When B is selected from 5-10 membered monocycloalkyl optionally substituted by one or more R b , A is selected from R 4 and R 6 are null; 3) When B is selected from 3-4 membered monocycloalkyl, or 3-10 membered heteromonocycloalkyl, A is selected from When R 4 is null and R 6 is not null, 3-4 membered monocycloalkyl or 3-10 membered heteromonocycloalkyl in B is substituted with one or more R b ; 4) When A is selected from-C 1～6 alkylene, B is selected from 5-12 membered heterospiro optionally substituted with one or more R b .
  3. 3. The compound of claim 1, wherein each R 1 、R 2 、R 3 is independently selected from H, -OH, halogen, -C 1～3 alkyl, -C 1～3 haloalkyl, or-C 1～3 hydroxyalkyl; And/or R 1 is halogen, R 2 is-OH; And/or R 1 is-OH, R 2 is halogen; And/or R 1 is F, R 2 is-OH; And/or R 1 is-OH, R 2 is F; And/or R 3 is H; And/or R 4 is selected from the group consisting of null, or-C 1～3 alkylene; and/or R 4 is null; And/or R 4 is-C 1～3 alkylene; and/or R 5 is selected from H, or-C 1～3 alkyl; And/or R 6 is selected from the group consisting of null, -C (O) -C 1～3 alkylene, -S (O) 2 -、-S(O) 2 -C 1～3 alkylene, or-C 1～3 alkylene; And/or R 6 is selected from the group consisting of null, -C 1～3 alkylene; and/or, R 7 is selected from-C 3～8 alkyl; And/or the number of the groups of groups, -C 1～3 alkylene-NH-C 3～8 alkyl optionally substituted with one or more R a ; And/or the number of the groups of groups, Selected from the group consisting of-N (R 5 ) -, optionally substituted with one or more R a , -C 1～3 alkylene-N (R 5 ) -, optionally substituted with one or more R a , -N optionally substituted with one or more R a (R 5 )-C 1～3 alkylene-, C 1～3 alkylene-N optionally substituted with one or more R a (R 5 )-C 1～3 alkylene-), -N (R 5 ) -C (O) -, optionally substituted with one or more R a , -C 1～3 alkylene-N (R 5 ) -C (O) -, optionally substituted with one or more R a , -N optionally substituted with one or more R a (R 5 )-C(O)-C 1～3 alkylene-, or-C 1～3 alkylene-N optionally substituted with one or more R a (R 5 )-C(O)-C 1～3 alkylene-; And/or the number of the groups of groups, Selected from the group consisting of And/or, ring a' is selected from 7-8 membered heterocycloalkylene optionally substituted with one or more R a ; And/or the number of the groups of groups, Is optionally substituted with one or more R a : And/or the number of the groups of groups, R 6 in (3) is-C 1～6 alkylene; And/or the number of the groups of groups, Is optionally substituted with one or more R a : And/or the number of the groups of groups, Selected from 5-6 membered cycloalkylene optionally substituted with one or more R a ; And/or the number of the groups of groups, Is optionally substituted with one or more R a And/or the number of the groups of groups, Selected from- (4-10) membered heterocycloalkylene- (5-10) membered cycloalkylene optionally substituted with one or more R a ; And/or the number of the groups of groups, Is optionally substituted with one or more R a And/or the number of the groups of groups, Selected from-N (R 5 ) - (5-10) membered cycloalkylene optionally substituted with one or more R a , -N (R 5 ) - (5-10) membered heterocycloalkylene optionally substituted with one or more R a , -C 1～3 alkylene-N (R 5 ) - (5-10) membered cycloalkylene optionally substituted with one or more R a , -C 1～3 alkylene-N (R 5 ) - (5-10) membered heterocycloalkylene optionally substituted with one or more R a , -N (R 5 )-C 1～3 alkylene- (5-10) cycloalkylene optionally substituted with one or more R a , -N (R 5 )-C 1～3 alkylene- (5-10) heterocycloalkylene) optionally substituted with one or more R a , -C 1～3 alkylene-N (R 5 )-C 1～3 alkylene- (5-10) cycloalkylene optionally substituted with one or more R a , -C 1～3 alkylene-N (R 5 )-C 1～3 alkylene- (5-10) heterocycloalkylene) optionally substituted with one or more R a , -N (R 5 ) -C (O) - (5-10) membered cycloalkylene optionally substituted with one or more R a , -N (R 5 ) -C (O) - (5-10) membered heterocycloalkylene optionally substituted with one or more R a , -C 1～3 alkylene-N (R 5 ) -C (O) - (5-10) membered cycloalkylene optionally substituted with one or more R a , or-C 1～3 alkylene-N (R 5 ) -C (O) - (5-10) membered heterocycloalkylene optionally substituted with one or more R a ; And/or the number of the groups of groups, In (a) and (b) Is optionally substituted with one or more R a And/or the number of the groups of groups, Selected from the group consisting of And/or, in the compound shown in the formula (I) Selected from the group consisting of And/or, in the compound shown in the formula (I) Is that And/or the number of the groups of groups, Is that
  4. 4. The compound of claim 1, wherein B is selected from 3-4 membered monocycloalkyl optionally substituted with one or more R b , or 3-10 membered heteromonocycloalkyl optionally substituted with one or more R b ; A is selected from And/or B is selected from 3-4 membered monocycloalkyl, or 5-8 membered heteromonocycloalkyl, wherein the 3-4 membered monocycloalkyl, or 5-8 membered heteromonocycloalkyl is optionally substituted with one or more of-C 1～3 haloalkyl, -C 1～3 hydroxyalkyl; A is selected from And/or, B is selected from 3-4 membered monocycloalkyl, wherein the 3-4 membered monocycloalkyl is optionally substituted with one or more of- (6-10) membered aryl, -C 1～3 haloalkyl, -C 1～3 hydroxyalkyl; A is selected from And/or B is selected from A is selected from And/or B is selected from 3-4 membered monocycloalkyl optionally substituted with one or more R b , or 3-10 membered heteromonocycloalkyl optionally substituted with one or more R b ; A is selected from And/or B is selected from A is selected from And/or B is selected from-C 2～10 alkenyl optionally substituted with one or more R b , 3-4 membered monocycloalkyl optionally substituted with one or more R b , 5-10 membered monocycloalkyl optionally substituted with one or more R b , 3-10 membered heteromonocycloalkyl optionally substituted with one or more R b , or 5-12 membered spirocyclic ring optionally substituted with one or more R b ; A is selected from And/or B is selected from the following groups optionally substituted with one or more R b : A is selected from And/or B is selected from A is selected from And/or B is selected from 3-4 membered monocycloalkyl optionally substituted with one or more R b , 5-10 membered monocycloalkyl optionally substituted with one or more R b , or 3-10 membered heteromonocycloalkyl optionally substituted with one or more R b ; A is selected from Wherein R 4 and R 6 are null; And/or B is selected from the following groups optionally substituted with one or more R b : A is selected from And/or B is selected from A is selected from And/or B is selected from 3-4 membered monocycloalkyl substituted with one or more R b , 5-10 membered monocycloalkyl substituted with one or more R b , or 3-10 membered heteromonocycloalkyl substituted with one or more R b ; A is selected from Wherein R 4 is null and R 6 is null or-C 1～6 alkylene; And/or B is selected from the following groups substituted with one or more R b : A is selected from Wherein R 4 is null, R 6 is null or-C 1～6 alkylene; and/or B is selected from A is selected from Wherein R 4 is null, R 6 is null or-C 1～6 alkylene; And/or B is selected from a 6-12 membered ring optionally substituted with one or more R b , a 6-12 membered heteroring optionally substituted with one or more R b ; A is selected from And/or B is selected from a- (4-6) -membered cycloalkyl- (3-6) -membered cycloalkyl ring, a- (4-6) -membered cycloalkyl- (3-6) -membered heterocycloalkyl ring, a- (4-6) -membered heterocycloalkyl- (3-6) -membered cycloalkyl ring, or a- (4-6) -membered cycloalkyl- (6-10) -membered aryl ring, wherein the- (4-6) -membered cycloalkyl- (3-6) -membered cycloalkyl ring, the- (4-6) -membered heterocycloalkyl- (3-6) -membered cycloalkyl ring, or the- (4-6) -membered cycloalkyl- (6-10) -membered aryl ring is optionally substituted with one or more-C 1～6 alkyl groups; A is selected from And/or B is selected from a 6-membered cycloalkyl-6-membered cycloalkyl ring, a 6-membered heterocycloalkyl-3-membered cycloalkyl ring, a 6-membered heterocycloalkyl-4-membered cycloalkyl ring, a 6-membered heterocycloalkyl-6-membered cycloalkyl ring, a 6-membered cycloalkyl-6-membered heterocycloalkyl ring, or a 4-membered cycloalkyl-6-membered aryl ring, wherein the 6-membered cycloalkyl-6-membered cycloalkyl ring, the 6-membered heterocycloalkyl-3-membered cycloalkyl ring, the 6-membered heterocycloalkyl-4-membered cycloalkyl ring, the 6-membered heterocycloalkyl-6-membered cycloalkyl ring, the 6-membered cycloalkyl-6-membered heterocycloalkyl ring, or the 4-membered cycloalkyl-6-membered aryl ring is optionally substituted with one or more-C 1～6 alkyl groups; A is selected from And/or B is selected from A is selected from And/or, B is selected from-C 1～10 alkyl substituted with one or more halo, -C 2～10 alkenyl optionally substituted with one or more R b , or-C 2～10 alkynyl optionally substituted with one or more R b ; and/or B is selected from And/or B is selected from a 5-12 membered spiro ring optionally substituted with one or more R b , a 5-12 membered heterospiro ring optionally substituted with one or more R b , a 5-12 membered bridged ring optionally substituted with one or more R b , a 5-12 membered heterobridged ring optionally substituted with one or more R b , a 5-12 membered fused ring optionally substituted with one or more R b , or a 5-12 membered fused ring optionally substituted with one or more R b ; and/or B is selected from a 5-10 membered spiro ring optionally substituted with one or more R b , a 5-10 membered heterospiro ring optionally substituted with one or more R b , a 5-10 membered bridged ring optionally substituted with one or more R b , a 5-10 membered heterobridged ring optionally substituted with one or more R b , a 5-10 membered fused ring optionally substituted with one or more R b , or a 5-10 membered fused ring optionally substituted with one or more R b ; and/or B is selected from the following structures optionally substituted with one or more R b : And/or, each R b is independently selected from-OH, -CN, oxo, halogen, -C 1～6 alkyl, -C 1～6 haloalkyl, -C 1～6 hydroxyalkyl, -C (O) -C 1～6 alkyl, -C 0～6 alkylene- (3-10) cycloalkyl, -C 0～6 alkylene- (6-10) aryl, -S (O) 2 - (6-10) aryl; And/or, each R b is independently selected from-OH, -CN, halogen, -C 1～6 alkyl, -C 1～6 haloalkyl, -C 1～6 hydroxyalkyl, -C (O) -C 1～3 alkyl, - (3-6) cycloalkyl, -C 1～3 alkylene- (6-8) aryl, -S (O) 2 - (6-8) aryl; and/or B is selected from the following structures: And/or, when a is selected from-C 1～6 alkylene, B is selected from the following groups optionally substituted with one or more R b : And/or, when A is selected from-C 1～6 alkylene, B is selected from
  5. 5. The compound according to any one of claims 1 to 4, wherein the compound of formula (I) has a structure of formula (II): Optionally, R 1 is —oh; And/or R 2 is F; And/or R 3 is H; and/or R 4 is null; And/or R 5 is H; And/or R 6 is null; And/or B is selected from-C 2～10 alkenyl optionally substituted with one or more R b , -C 2～10 alkynyl optionally substituted with one or more R b , 5-12 membered spiro optionally substituted with one or more R b , 5-12 membered bridged ring optionally substituted with one or more R b , or 5-12 membered fused ring optionally substituted with one or more R b ; and/or B is selected from the following structures optionally substituted with one or more R b : and/or B is selected from the following structures optionally substituted with one or more R b : and/or, each R b is independently selected from-OH, halogen, oxo, -CN, -C 1～3 alkyl, -C 1～3 haloalkyl, -C (O) -C 1～6 alkyl, -C 1～3 alkylene- (6-8) membered aryl; and/or, each R b is independently selected from-OH, halogen, oxo, -C 1～3 alkyl, -C 1～3 haloalkyl; and/or B is selected from the following structures: and/or B is selected from the following structures:
  6. 6. the compound according to any one of claims 1 to 4, wherein the compound of formula (I) has a structure of formula (III): wherein R 8 is selected from 3-4 membered monocycloalkyl, or 3-10 membered heteromonocycloalkyl; r 9 is selected from 6-10 membered aryl, or 3-10 membered cycloalkyl; Optionally, R 1 is —oh; And/or R 2 is F; And/or R 3 is H; and/or R 4 is null; And/or R 5 is H; And/or R 6 is null; And/or R 8 is selected from 3-4 membered monocycloalkyl, or 5-10 membered heteromonocycloalkyl; And/or R 9 is selected from 6-8 membered aryl, or 3-5 membered cycloalkyl; and/or-R 8 -R 9 is selected from
  7. 7. The compound according to any one of claims 1 to 4, wherein the compound of formula (I) has a structure of formula (IV): Optionally, R 1 is —oh; And/or R 2 is F; And/or R 3 is H; And/or B is selected from-C 2～10 alkenyl optionally substituted with one or more R b , 3-4 membered monocycloalkyl optionally substituted with one or more R b , 5-10 membered monocycloalkyl optionally substituted with one or more R b , 3-10 membered heteromonocycloalkyl optionally substituted with one or more R b , 5-12 membered spirocyclic ring optionally substituted with one or more R b , or 5-12 membered heterospirocyclic ring optionally substituted with one or more R b ; And/or B is selected from-C 2～10 alkenyl optionally substituted with one or more R b , 3-4 membered monocycloalkyl optionally substituted with one or more R b , 5-8 membered monocycloalkyl optionally substituted with one or more R b , 4-6 membered heteromonocycloalkyl optionally substituted with one or more R b , 5-10 membered spirocyclic ring optionally substituted with one or more R b , or 5-10 membered heterospirocyclic ring optionally substituted with one or more R b ; And/or B is selected from a 5-10 membered monocycloalkyl optionally substituted with one or more R b , or a 5-10 membered spirocyclic ring optionally substituted with one or more R b ; and/or B is selected from the following structures optionally substituted with one or more R b : and/or B is selected from the following structures optionally substituted with one or more R b : and/or B is selected from the following structures optionally substituted with one or more R b : And/or, each R b is independently selected from halogen, oxo, -C 1～6 alkyl, -C 0～6 alkylene-C 1～6 alkoxy, -C 1～6 haloalkyl, or 6-to 8-membered aryl; and/or B is selected from the following structures:
  8. 8. the compound according to any one of claims 1 to 4, wherein the compound of formula (I) has a structure represented by formula (V): Optionally, R 1 is —oh; And/or R 2 is F; And/or R 3 is H; And/or R 4 is-C 1～3 alkylene; And/or R 5 is H; And/or R 6 is null, -C (O) -, -S (O) 2 -C 1～3 alkylene, or-C 1～3 alkylene; And/or R 6 is null, -C (O) -, or-C 1～3 alkylene.
  9. 9. The compound of claim 8, wherein B is selected from a 5-10 membered spiro ring optionally substituted with one or more R b , a 5-10 membered heterospiro ring optionally substituted with one or more R b , a 5-10 membered bridged ring optionally substituted with one or more R b , a 5-10 membered bridged ring optionally substituted with one or more R b , a 5-10 membered fused ring optionally substituted with one or more R b , or a 5-10 membered fused ring optionally substituted with one or more R b ; and/or B is selected from the following structures optionally substituted with one or more R b : and/or B is selected from the following structures optionally substituted with one or more R b : And/or, each R b is independently selected from halogen, -CN, oxo (=o), -C 1～6 alkyl, -C 1～6 haloalkyl, -C 0～6 alkylene- (6-10) membered aryl, or-S (O) 2 - (6-10) membered aryl; And/or, each R b is independently selected from halogen, -CN, oxo (=o), -C 1～3 alkyl, -C 1～3 haloalkyl, -C 0～3 alkylene- (6-8) membered aryl, or-S (O) 2 - (6-8) membered aryl; and/or B is selected from the following structures: and/or B is selected from the following structures: And/or B is selected from 3-4 membered monocycloalkyl optionally substituted with one or more R b , 3-10 membered heteromonocycloalkyl optionally substituted with one or more R b , 6-20 membered bicyclic ring optionally substituted with one or more R b , or 6-20 membered heterobicyclic ring optionally substituted with one or more R b ; and/or B is selected from 3-4 membered monocycloalkyl optionally substituted with one or more R b , or 10-15 membered bicyclo optionally substituted with one or more R b ; And/or, each R b is independently selected from-C 1～6 alkyl, -C 1～6 haloalkyl, or-C 1～3 hydroxyalkyl; and/or B is selected from
  10. 10. The compound according to any one of claims 1 to 4, wherein the compound of formula (I) has a structure of formula (VI): Optionally, R 1 is —oh; And/or R 2 is F; And/or R 3 is H; And/or R 4 is-C 1～3 alkylene; And/or R 5 is H; And/or R 6 is selected from the group consisting of null, or-C 1～3 alkylene; And/or R 6 is null; And/or, R 7 is-C 3～8 alkyl; and/or-R 6 -R 7 is selected from
  11. 11. The compound according to any one of claims 1 to 4, wherein the compound of formula (I) has a structure of formula (VII): B is selected from-C 2～10 alkenyl optionally substituted with one or more R b , or-C 2～10 alkynyl optionally substituted with one or more R b ; optionally, R 4 is selected from null; And/or R 6 is selected from null; and/or R 5 is selected from H; And/or, B is selected from-C 2～8 alkenyl optionally substituted with one or more R b , or-C 2～8 alkynyl optionally substituted with one or more R b ; and/or B is selected from
  12. 12. The compound of claim 1, wherein the compound of formula (I) comprises the structure:
  13. 13. the compound of claim 1, wherein the compound of formula (I) comprises the structure:
  14. 14. Use of a compound according to any one of claims 1 to 13 for the preparation of a PTPN protein inhibitor.
  15. 15. A PTPN protein inhibitor comprising a compound of any one of claims 1 to 13, and optionally pharmaceutically acceptable adjuvants, carriers, vehicles.
  16. 16. A PROTAC medicament comprising a compound according to any one of claims 1 to 13, a linker and a ubiquitin ligase ligand, said compound and ubiquitin ligase ligand being linked by said linker.
  17. 17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, and optionally pharmaceutically acceptable adjuvants, carriers, vehicles.
  18. 18. Use of a compound according to any one of claims 1 to 13, a PTPN protein inhibitor according to claim 15, a PROTAC medicament according to claim 16, or a pharmaceutical composition according to claim 17, said use comprising: inhibit PTPN protein, and/or Immunotherapy, and/or Preventing and/or treating PTPN protein related diseases, and/or Preparation of an agent that inhibits PTPN protein, and/or Preparation PROTAC of a medicament, and/or Preparation of immunotherapeutic drugs, and/or Preparing a medicament for preventing and/or treating PTPN protein related diseases; optionally, the treating a PTPN protein-related disease is selected from cancer, metabolic disease.

Description

Compounds for inhibiting PTPN proteins and uses thereof Technical Field The application belongs to the technical field of biological medicines, and particularly relates to a compound for inhibiting PTPN protein and application thereof, and more particularly relates to a compound for inhibiting PTPN protein, a PTPN protein inhibitor, a pharmaceutical composition and application thereof. Background PTPN proteins are a class of non-receptor type protein tyrosine phosphatases that play an important role in cell signaling, for example, in regulating cell growth, development, differentiation, survival and migration, and the like, and certain members of the PTPN family have potential roles in cancer immunotherapy, such as PTPN1, PTPN2, PTPN12 and PTPN22, with expression in esophageal, gastric and colorectal cancers being involved in the occurrence of disease. PTPN2 (also known as TCPTP or T cell protein tyrosine phosphatases) exerts a synergistic anti-inflammatory effect in a variety of inflammatory cells and regulates the development and differentiation of immune cells. Furthermore, the expression level of PTPN2 is closely related to the occurrence and prognosis of certain cancers, for example in pancreatic adenocarcinoma, high expression of PTPN2 is related to a worse prognosis, and it is possible to promote cancer progression by activating JAK-STAT signaling pathways. PTPN1 (protein tyrosine phosphatase 1, also known as T cell protein tyrosine phosphatase) plays an important role in regulating cell signaling, for example during activation, proliferation and differentiation of immune cells. PTPN1 is involved in regulating intracellular signaling, particularly in T cell development and function, by dephosphorylating a variety of substrate proteins. Furthermore, the expression level of PTPN1 is up-regulated in certain cancers, possibly related to proliferation, survival and metastasis of tumor cells. Therefore, development of a PTPN protein inhibitor has potential in treating diseases such as cancer. Disclosure of Invention The present application aims to solve at least one of the technical problems existing in the prior art to at least some extent. To this end, the present application provides a compound for inhibiting a PTPN protein and uses thereof. In a first aspect of the present application, the present application provides a compound of formula (I), or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof: Wherein each R 1、R2、R3 is independently selected from H, -OH, halogen, -C 1～6 alkyl, -C 1～6 haloalkyl, or-C 1～6 hydroxyalkyl; A is selected from the group consisting of-C 1～6 alkylene, * Is connected with B; ring a' is selected from 7-10 membered heterocycloalkylene optionally substituted with one or more R a; Ring A' is selected from 5-6 membered cycloalkylene optionally substituted with one or more R a, 5-6 membered heterocycloalkylene optionally substituted with one or more R a; Ring A' "is selected from 5-10 membered cycloalkylene optionally substituted with one or more R a, 5-10 membered heterocycloalkylene optionally substituted with one or more R a; Ring L is selected from 4-10 membered heterocycloalkylene optionally substituted with one or more R a; r 4 is selected from the group consisting of a null, or-C 1～6 alkylene; r 5 is selected from H, or-C 1～6 alkyl; R 6 is selected from the group consisting of null, -C (O) -C 1～6 alkylene, -S (O) 2-、-S(O)2-C1～6 alkylene, or-C 1～6 alkylene; R 7 is selected from-C 1～10 alkyl; B is selected from the group consisting of empty, -C 1～10 alkyl optionally substituted with one or more halo, -C 2～10 alkenyl optionally substituted with one or more R b, -C 2～10 alkynyl optionally substituted with one or more R b, -3-4 membered monocycloalkyl optionally substituted with one or more R b, -5-10 membered monocycloalkyl optionally substituted with one or more R b, -3-10 membered heteromonocycloalkyl optionally substituted with one or more R b, -6-20 membered bicyclic optionally substituted with one or more R b, -6-20 membered heterobicyclic optionally substituted with one or more R b, -5-12 membered spirocyclic optionally substituted with one or more R b, -5-12 membered heterospirocyclic optionally substituted with one or more R3496, -5-12 membered bridged ring optionally substituted with one or more R b, -5-12 membered heterobridged ring optionally substituted with one or more R b, -5-12 membered heterobridged ring optionally substituted with one or more R b -12 membered and optionally substituted with one or more R b; B is empty and A is selected from Each R a is independently selected from-OH, halogen, oxo (=o), -C 1～6 alkyl, -C 1～6 haloalkyl, -C 1～6 alkoxy; Each R b is independently selected from the group consisting of-OH, -C 0～6 alkylene-CN, halogen, oxo (= O), -S (O) 2-C1～6 alkyl, -C 1～6 alkyl, -C 1～6 haloalkyl, -C 1～6 hydroxyalkyl, -C 0～6 alkylene-C 1～6 alkoxy, -C 2～10 alkenyl, -C 2～10 alkynyl, -C (O) -C 1～6 alkyl, -C